Estrella Immunopharma, Inc. — Form 8-K
Filed October 29, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Estrella Immunopharma hired Cynthia Pussinen as CEO/Chairperson effective October 25, 2026, with base salary starting at $250K (escalating to $400K–$525K based on funding milestones), 60% annual bonus target, and 1M stock options vesting over 4 years. Simultaneously, Cheng Liu was demoted from CEO to President/Chief Scientific Officer, and Peter Xu (CFO) retained but with amended terms. All three executives have deferred base salary since May 22, 2026, pending financing. Severance includes 12 months salary plus prorated bonus; change-in-control triggers 100% equity acceleration.
Why this rating
Leadership restructuring is material for governance but company size ($20.5M market cap) and pre-existing officer corps mean moderate operational impact. Cash deferral signals liquidity stress; $250K base salary is ~1.2% of market cap, immaterial. No transformational deal announced.
See more from October 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.